Oncotarget cover image

Oncotarget

UGDH in Clinical Oncology and Cancer Biology

Oct 4, 2023
In this podcast, researcher Meghan J. Price discusses UDP-glucose dehydrogenase (UGDH) and its role in tumor progression. The review paper explores UGDH as a molecular indicator of tumor progression, its involvement in cancer signaling pathways, and potential therapeutic targets and prognostication markers.
02:10

Episode guests

Podcast summary created with Snipd AI

Quick takeaways

  • UDP-glucose dehydrogenase (UGDH) can serve as a molecular indicator of tumor progression in multiple cancer types.
  • Inhibiting UGDH and its downstream products could be a potential therapeutic strategy for cancer treatment.

Deep dives

UGDH as a molecular indicator of tumor progression

A new review paper published in Enco Targets Vol. 14 discusses the role of UDP-glucose dehydrogenase (UGDH) as a molecular indicator of tumor progression in multiple cancer types. The researchers from various institutions classify UGDH as an enzyme involved in key canonical cancer signaling pathways and highlight its potential as a prognostication marker in oncology. They also identify methods to inhibit UGDH and its downstream products, positioning it as a therapeutic target in cancer biology.

Remember Everything You Learn from Podcasts

Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
App store bannerPlay store banner